HD Insights™

Vol. 12 - Fall 2015

Issue link: http://www.e-digitaleditions.com/i/579310

Contents of this Issue

Navigation

Page 5 of 15

6 HD Insights, Vol. 12 SPONSOR STUDY NAME/ IDENTIFIER STUDY AGENT PHASE PRINCIPAL INVESTIGATOR, CONTACT DESIGN TRIAL LENGTH SITES STATUS Raptor Pharmaceuticals CYST-HD Cysteamine bitartrate delayed-release capsules (RP103) II/III Christophe Verny, MD Double-blind, placebo-controlled study to be followed by an open-label extension study 36 months 8 total - France Enrollment complete, study ongoing Auspex Pharmaceuticals FIRST-HD SD-809 Extended Release III Samuel Frank, MD Huntington Study Group: 800-487-7671 Randomized, double-blind study to determine whether SD-809 ER tablets are effective in the treatment of chorea associated with HD. To be followed by an open-label, long-term safety study 12 weeks 7 total - United States Study complete, top line results released Auspex Pharmaceuticals ARC-HD SD-809 Extended Release III Samuel Frank, MD Huntington Study Group: 800-487-7671 Open-label, long-term safety study of SD-809 ER 58 weeks 7 total - United States Enrollment complete, study ongoing Assistance Publique - Hôpitaux de Paris REVHD Resveratrol III Tiffany Monier, MS +33 1 57 27 42 22 Randomized, placebo-controlled study to evaluate the therapeutic potential of Resveratrol on caudate volume in HD patients, using volumetric MRI 1 year 1 total - France Currently enrolling Assistance Publique - Hôpitaux de Paris NEUROHD Olanzapine, Tetrabenazine, and Tiapride III Anne-Catherine Bachoud Levi, PhD +33 (0)1 49 81 23 01 Randomized, controlled study to compare the beneficial and adverse effects of 3 different neuroleptics in HD 1 year 1 total - France Currently enrolling Copyright © Huntington Study Group 2015. All rights reserved. Clinical Trials, cont... To update or add a clinical trial, please e-mail editor@hdinsights.org. Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/ H D I N S I G H T S Teva CNS is committed to continued research and development of its product portfolio and to the development of medicines aimed at meeting the specific needs of the patient communities it serves. Teva's legacy in CNS is grounded in its commitment to ongoing collaboration with academia, medical institutions and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases. H D I N S I G H T S T M T H A N K S T E V A F O R I T S G E N E R O U S S U P P O R T

Articles in this issue

Links on this page

Archives of this issue

view archives of HD Insights™ - Vol. 12 - Fall 2015